← Back to Search

Digital Intervention for Binge Eating Disorder in Black Women

N/A
Waitlist Available
Led By Rachel Goode, PhD,MPH
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial found Black women are more likely to binge eat & struggle to get effective treatment. To reduce weight-related concerns, culturally-relevant treatments for binge eating must be available to Black women.

Who is the study for?
This trial is for Black women over 18 with obesity (BMI ≥ 30) who binge eat at least once a week and live or work within 30 miles of Kannapolis, NC. They must use a smartphone and complete a questionnaire. It's not for those in other weight programs, using drugs/alcohol heavily, pregnant, treating substance abuse/eating disorders, or with anorexia history.
What is being tested?
'Centering Appetite' is being tested as a culturally-relevant digital treatment to help Black women manage obesity and binge eating. The study aims to address the high rates of obesity by focusing on reducing binge eating behaviors through accessible technology.
What are the potential side effects?
Since 'Centering Appetite' is a behavioral intervention rather than medication, side effects may include emotional discomfort or stress due to changes in eating habits but are generally considered low-risk compared to drug treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Attendance: Percentage of Intervention Sessions Attended
Feasibility (Recruitment): Total Number of Eligible Adults Enrolled in the Study
Retention: Percentage of Participants Retained in the Study
Secondary study objectives
Change from Baseline to Month 3 in weight regain
Change from Baseline to Month 6 in weight regain
Change in number of Binge Eating Episodes from Baseline to Month 3
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Centering Appetite Intervention, Then Attention- Control GroupExperimental Treatment1 Intervention
Participants randomized to the attention-control group will participate remotely via a smartphone app and online lessons. The intervention will build participants' self-efficacy to reduce binge eating and to assist them in preventing weight gain.
Group II: Attention- Control Group, Then Centering Appetite InterventionActive Control1 Intervention
Participants randomized to the centering appetite intervention group will receive weekly psychoeducation emails about general wellness topics, discussion of binge eating, diet, and physical activity.

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,555 Previous Clinical Trials
4,298,473 Total Patients Enrolled
65 Trials studying Obesity
58,383 Patients Enrolled for Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,446 Previous Clinical Trials
4,331,772 Total Patients Enrolled
469 Trials studying Obesity
589,951 Patients Enrolled for Obesity
Rachel Goode, PhD,MPHPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Media Library

Centering Appetite Clinical Trial Eligibility Overview. Trial Name: NCT05693896 — N/A
Obesity Research Study Groups: Centering Appetite Intervention, Then Attention- Control Group, Attention- Control Group, Then Centering Appetite Intervention
Centering Appetite 2023 Treatment Timeline for Medical Study. Trial Name: NCT05693896 — N/A
Obesity Clinical Trial 2023: Centering Appetite Highlights & Side Effects. Trial Name: NCT05693896 — N/A
~40 spots leftby Dec 2025